Q2 EPS Estimate for ARS Pharmaceuticals Lowered by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - William Blair decreased their Q2 2025 earnings estimates for shares of ARS Pharmaceuticals in a report issued on Wednesday, May 14th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings per share of ($0.44) for the quarter, down from their previous estimate of ($0.32). William Blair has a "Outperform" rating on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals' Q3 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.62) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.63) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million for the quarter, compared to analyst estimates of $7.48 million.

SPRY has been the topic of several other reports. Oppenheimer initiated coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 price target on the stock. Scotiabank assumed coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a "sector outperform" rating and a $30.00 target price on the stock. Finally, Wall Street Zen lowered ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY traded up $0.46 during mid-day trading on Monday, reaching $14.98. 2,307,209 shares of the company traded hands, compared to its average volume of 1,253,814. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The firm has a market cap of $1.47 billion, a PE ratio of -29.37 and a beta of 0.84. The stock has a fifty day simple moving average of $13.61 and a 200-day simple moving average of $12.87.

Insiders Place Their Bets

In other ARS Pharmaceuticals news, insider Alexander A. Fitzpatrick sold 102,969 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the sale, the insider now owns 89,613 shares in the company, valued at approximately $1,263,543.30. The trade was a 53.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 49,600 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $2,357,978.66. The trade was a 19.08% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 382,571 shares of company stock worth $5,177,904. 33.50% of the stock is owned by insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of large investors have recently made changes to their positions in SPRY. Wellington Management Group LLP raised its stake in ARS Pharmaceuticals by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 163,252 shares of the company's stock valued at $1,722,000 after purchasing an additional 917 shares during the period. Rhumbline Advisers raised its stake in ARS Pharmaceuticals by 2.9% during the 4th quarter. Rhumbline Advisers now owns 65,163 shares of the company's stock valued at $687,000 after purchasing an additional 1,824 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in ARS Pharmaceuticals by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company's stock valued at $217,000 after purchasing an additional 1,962 shares during the period. Mariner LLC raised its stake in ARS Pharmaceuticals by 5.8% during the 4th quarter. Mariner LLC now owns 35,908 shares of the company's stock valued at $379,000 after purchasing an additional 1,972 shares during the period. Finally, Bank of New York Mellon Corp raised its position in ARS Pharmaceuticals by 1.5% during the first quarter. Bank of New York Mellon Corp now owns 132,213 shares of the company's stock valued at $1,663,000 after buying an additional 1,975 shares during the period. Institutional investors and hedge funds own 68.16% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.